Biopharmaceutical company, CytomX Therapeutics Inc., is making strides in cancer treatment with their antibody therapeutics based on their Probody technology platform. The company's impressive product line includes CX-2009, used in the Phase II clinical trials for the treatment of breast cancer; CX-2029 utilized in Phase II for the treatment of various cancers including squamous non-small cell lung cancer, head and neck squamous cell carcinoma, and more; CX-2051, which targets epithelial cell adhesion-molecule-expressing epithelial cancers; and CX-801, a dually masked and conditionally activated interferon alpha-2b therapy for various tumor types. Additionally, the company has developed BMS-986288, an anti-CTLA-4 Probody drug under clinical trials for treating solid tumors, and CX-904, a conditionally activated epidermal growth factor receptor for treating solid tumor. The company is backed by strategic collaborations with top players like Amgen, Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals, among others. Founded in 2008, the company is headquartered in South San Francisco, California, and has been instrumental in developing novel cancer treatments.
CytomX Therapeutics's ticker is CTMX
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 51-200 employees working at CytomX Therapeutics
It is cytomx.com
CytomX Therapeutics is in the Healthcare sector
CytomX Therapeutics is in the Biotechnology industry
The following five companies are CytomX Therapeutics's industry peers: